Immunogenicity Assays - Abzena

Immunogenicity Assays

Helping you to better understand your drug candidate.

Start smarter with Abzena.

The evaluation of a drug candidate’s developability is a pivotal stage in the drug development process. Therapeutic antibodies and proteins can induce an immune response. Immunogenicity risk assessment is therefore a crucial aspect of biopharmaceutical drug development. Abzena’s experts offer immunogenicity assays, that help you better understand your drug.

Contact Us

Although the potential for immunogenicity of therapeutic antibodies and proteins has been significantly reduced through the application of protein engineering technologies, clinical data shows that many biopharmaceuticals still induce an immune response in patients. Immunogenicity therefore remains a concern for companies developing new products and for the regulatory agencies asked to approve their use.

Our next-generation EpiScreen® 2.0 platform is Abzena’s innovative answer to these challenges. We utilize flow cytometry technology for precise, multi-dimensional immunogenicity assays. We provide a comprehensive suite of bioassays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.

Smarter immunogenicity testing

When it comes time to evaluate the immunogenic risk of your biopharmaceutical program, our newly enhanced EpiScreen® 2.0 platform offers a comprehensive suite of assays that can predict, and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.

To learn more and access our info sheet click the button below.

Discover EpiScreen® 2.0

What sets our immunogenicity assessment services apart?

  • Industry-leading immunogenicity assessments provide data-rich readouts that:
    • Generate a risk assessment profile of a client’s molecule and helps inform clinical progression strategies
    • Facilitate lead candidate selection, e.g. as part of a developability package
    • Allow derisking of a molecule by determining areas within the protein sequence that can be engineered to reduce immunogenicity risk
    • Can be customized to address specific immunogenicity and MoA-associated questions
  • Immunogenicity assessment is highly recommended to support a strong IND submission, especially for novel therapeutics
  • EpiScreen® 2.0 offers smarter ex vivo assessment of immunogenicity

Discover EpiScreen® 2.0

EpiScreen® 2.0 encompasses a package of assays that allow an accurate and sensitive way to assess the potential immunogenicity of proteins and antibodies ex vivo using a variety of methods such as measuring CD4+ T cell responses, the primary drivers of memory-based immunogenicity or evaluating MHC Class II peptide presentation.

EpiScreen® 2.0: Smarter Immunogenicity Testing

A comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.

Learn More

EpiScreen® 2.0 Time Course T Cell Assay

These assays have been used extensively as a standard for preclinical immunogenicity testing.

Learn More

EpiScreen® 2.0 DC:T Cell Assay

Assessing antibody immunogenicity and the 'adjuvant effect' of different product formulations on immunogenicity.

Learn More

Episcreen® 2.0 Cytokine Screen™

We can assess a biopharmaceutical product's immune modulating potential by assessing its ability to stimulate cytokine production.

Learn More

EpiScreen® 2.0 T Cell Epitope Mapping

Identifying CD4+ T cell epitopes within protein sequences in order to design deimmunized variants.

Learn More

EpiScreen® 2.0 MAPPs

Identifying MHC Class II bound peptides processed and presented by dendritic cells (DCs) from therapeutic proteins/mAbs.

Learn More

TCED™ & iTope-AI

A powerful tool for in silico immunogenicity assays and design of deimmunized proteins & antibodies.

Learn More

Custom Immunology Assays

Abzena brings together expertise in immunology with the technology required to perform bespoke immunology assays.

Learn More

Blog: Immunogenicity Assessment FAQs

Discover our blog of frequently asked questions on immunogenicity assays and addressing the complexities of immunogenicity in biologic therapies.

Learn More

Related

Analytics & Bioassays

Our expertise in analytics and bioassays focuses on giving you the rapid insight to make informed decisions during your drug development journey.

Learn More

Cell Line Development

AbZelectPRO™ is our cell line development solution which can rapidly progress therapeutic protein & recombinant vaccine programs from DNA to RCB in 10 weeks.

Learn More

Formulation Development

With a focus on aligning your drug candidates to the ideal target product profile (TPP) we develop a comprehensive range of formulation development packages.

Learn More